C7 Antibody (Polyclonal)

A goat antiserum raised against human C7 protein.


Product Specifications

Citations 5
Clonality

Polyclonal

Immnogen
Applications See citations and technical data sheet for application info.
Concentration > 40 mg/mL
Conjugate Unconjugated
Cross Reactivity

Human, Baboon, Guinea Pig, Cat, Rabbit, Hamster, Horse

Ordering Information

For Research Use Only in the United States. Not for use in diagnostic procedures.
Catalog Number A308
Catalog Number (CE) N/A
Size 2.0 mL
Price (USD) $340.00
Price (EURO) 305,00 €

Contact us

US Phone+1 (858) 552 1100
EU Phone+353 (91) 412 474
US Emailcontact-us@quidelortho.com
EU Emailcontact-emea@quidelortho.com

Specifications

Description

A goat antiserum raised against human C7 protein.

Size 2.0 mL
Concentration

> 40 mg/mL

Applications See citations and technical data sheet for application info.
Form Liquid. Whole Antiserum. ≤ 0.1% Sodium Azide
Clonality Polyclonal
Immunogen Highly purified human C7 protein
Conjugate Unconjugated
Cross Reactivity Human, Baboon, Guinea Pig, Cat, Rabbit, Hamster, Horse
Isotype Goat IgG
Purity N/A
Source

Goat

Specificity The anti-human C7 polyclonal antisera was tested against normal human plasma by double immunodiffusion, one-dimensional immunoelectrophoresis, quantitative radial immunodiffusion, and quantitative rocket immunoelectrophoresis. The antiserum was determined to be monospecific for C7 at varying concentrations.
Storage

Short term (30 days) 4˚C. Long term at or below –20˚C.

Background

C7 is a glycoprotein which is present in normal human serum/plasma at approximately 55 µg/mL. Primarily synthesized in the liver, C7 is a single-chain protein with a molecular weight of approximately 95 kD. This complement protein is key for the continued formation of the SC5b-9 complex after C5b binds to C6. With activation of the classical or alternative pathways of the complement system, C5 convertase cleaves the C5 chain into C5a and C5b. C5b remains bound to the convertase and will combine with C6 to form a C5b,6 complex. This complex normally interacts with C7 to form C5b,6,7 that becomes partially embedded in the target cell outer membrane. If C7 is limited, the C5b,6 will dissociate from the C5 convertase. This complex is relatively stable in free-solution and can be purified. This fluid-phase C5b,6 complex can combine with C7 in the presence of biological or artificial membranes to form a membrane bound C5b,6,7 complex, which can subsequently bind C8 and multiple C9 molecules completing the terminal pathway. The C5b,6,7,8,9, or C5b-9 complex, is also known as the Membrane Attack Complex (MAC), which causes irreversible damage to the target cell membrane.

Citations

Title Year Applications Sample Species Sample Sample Details

CspA from Borrelia burgdorferi inhibits the terminal complement pathway.

2013

IF

Bacteria

Borrelia burgdorferi

Inhibition of aberrant complement activation by a dimer of acetylsalicylic acid.

2015

ELISA, WB

Human

Serum

Acetyl salicylic acid dimer 5,5'-methylenebis(2-acetoxybenzoic acid) (DAS)

Use of a genetic isolate to identify rare disease variants: C7 on 5p associated with MS

2009

Radial immunodiffusion

Human

Plasma

Use of a genetic isolate to identify rare disease variants: C7 on 5p associated with MS

2009

Radial immunodiffusion

Human

Serum

Binding of vitronectin by the Moraxella catarrhalis UspA2 protein interferes with late stages of the complement cascade

2006

WB

Human

Serum

Moraxella catarrhalis